The LIGHTLas 810 - Multi-Purpose 810nm diode laser photocoagulator

The LIGHTLas 810 is a next generation multi-purpose 810nm diode laser photocoagulator designed for use by ophthalmic surgeons for the treatment of various Retinal and Glaucoma diseases.

It is one of the safest and most versatile single frequency lasers in the ophthalmic market due to its unique sp-mode™ and conventional continuous wavelength modalities.

Being developed to suit surgeons, the LIGHTLas 810 was developed using the latest technologies. Being a semiconductor diode laser, the LightLas 810 is a reliable product that will provide the ophthalmologist with many years of trouble free operation, and coming with a case, can be easily transported to other hospitals and clinics.

CLINICAL INFORMATION

INFRARED -810 NM WAVELENGTH

The infrared 810nm (commonly referred to as the Diode Laser) is a wavelength of unique characteristics, with niche clinical applications, and a great alternative to 532green and 670red wavelengths espe‐ cially when a deep penetration is re‐ quired. However due to the invisible properties, the 810nm is a wavelength that requires more understanding and expertise than the visible wavelengths, hence the reason why it has not gained the mass popularity.

The lesions produced by 810nm lasers are not immediately noticeable as the same lesions produced by green lasers. Com‐ monly, the lesions take a few days to ap‐ pear (depending on the patient), and once they become apparent, they may appear indistinguishable, both in look and clinical feature to the lesions produced by green lasers. During the treatment, the physician can monitor this effect and adjust the power settings by referring to the colour of the retinal lesion, which will usually appear slightly grey.

The 810nm wavelength is less absorbed by melanin than that of the green wave‐ lengths (532nm & 514nm); thus patients with low pigmentation (fair skin) may require higher power settings to photo‐ coagulate the tissue. However, for pa‐ tients with high pigmentation, the differ‐ ence between 810nm and green (532nm & 514nm) wavelengths is negligible.

Because of the invisible 810nm spectrum the diode laser has the advantages of penetrating through sclera, and excessive haemorrhage hance the wavelength has established itself as a standard in niche laser applications such as Retinopathy of Prematurity (ROP), Transscleral Cylcopho‐ tocoagulation or Transpupillary Thermo‐ Therapy, known more commonly as TTT (in treatment of ocular tumours) and CNV and in treatment some AMD cases.

TTT, relies on heat generation from en‐ dogenous pigment (hyperthermia princi‐ ple) for the treatment of Ocular Tumours and Choroidal Neovascularization (CNV).

Transscleral Cylcophotocoagulation (also known as TSCPC) of the ciliary processes. The ciliary body of the eye, which creates aqueous fluid, is treated with a laser to decrease production of aqueous. TSCPC has been demonstrated to be a safe and highly effective method for low‐ ering intraocular pressure (IOP) in pa‐ tients with severe uncontrolled glaucoma where previous medications and treat‐ ments have not shown to be effective.

The infrared 810nm wavelength is the versatile alternative in deep penetration.

Wavelength Benefits:

Highly absorbed by the melanin present in the Retinal Pigment Epithelium

Well absorbed by haemoglobin

Clinical Assets:

Good transmission through haemorrhages and vitreous opacities

Good penetration through sclera

Main Clinical Applications

Retinal Photocoagulation

Diabetic Retinopathy

Central serous chorio-retinaopathy

Diabetic Macular Edema

Central/Branch Retinal Vein Occlusion

Retinopathy of Prematurity (ROP)

Retinal Tears, Holes, and Detachments

Endophotocoagulation

Glaucoma

Cyclophotocoagulation

Laser Trabeculoplasty

Laser Iridotomy

Peripheral Iridectomy

Sub-Threshold Photocoagulation Laser Trabeculoplasty (spLT)

Ocular Tumors

Transpupillary Thermo-Therapy (TTT)